血清miR-210和miR-375在非小细胞肺癌患者中的表达变化情况

摘要

目的探讨血清miR-210和miR-375在非小细胞肺癌(NSCLC)患者中的表达变化情况.方法以25例NSCLC患者(NSCLC组)和14例健康志愿者(对照组)为研究对象,随机抽取6例NSCLC组和6例对照组的血液标本组成筛选实验,应用实时荧光定量PCR(RT-qPCR)检测9种miRNA(miR-182、miR-126、miR-31、miR-21、miR-221、miR-200b、miR-183、miR-210、miR-375)的表达水平,筛选出表达异常的miRNA为目标miRNA后,继续检测其在剩余标本中的表达水平,并采用受试者工作特征曲线(ROC曲线)评价其诊断效能.结果筛选实验发现,miR-210和miR-375在NSCLC组血清中的相对表达均升高,差异有统计学意义(P＜0.05),其他7种miRNA表达量趋势与已报道文献不符,选择miR-210和miR-375继续验证剩余标本,发现NSCLC患者中的肺腺癌组miR-210相对表达量较对照组升高,差异有统计学意义(P＜0.05),肺鳞癌组与对照组比较,差异无统计学意义(P＞0.05);miR-375在肺鳞癌和肺腺癌组中的相对表达量与对照组比较,差异均无统计学意义(P＞0.05).根据血清miR-210表达水平绘制ROC曲线,曲线下面积为0.737 5(95％CI:0.498 3～0.976 7,P=0.091 4),诊断准确性中等.结论miR-210在肺腺癌组高表达,可能成为诊断肺腺癌的新型肿瘤标志物;miR-375在辅助诊断肺癌的价值仍待进一步探讨.%Objective To investigate the expression levels of serum miR-210and miR-375in patients with non-small cell lung cancer (NSCLC).Methods A total of 25NSCLC patients (NSCLC group) and 14healthy volunteers (control group) were enrolled in this study.The relative expression levels of 9miRNAs (miR-182, miR-126, miR-31, miR-21, miR-221, miR-200b, miR-183, miR-210and miR-375) in 6 NSCLC patients and 6healthy volunteers were measured by RT-qPCR.The dysregulated miRNAs will be selected as candidate miR-NAs.The diagnostic value were evaluated by ROC curve.Results Compared with control group, 2 (miR-210and miR-375) out of 9miRNAs were up-regulated in NSCLC group, and the differences were statistically significant (P＜0.05), while the other 7miRNAs were not consistent with the reported literatures.Therefore, miR-210and miR-375were selected as candidate miRNAs.We found that the relative expression level of miR-210in the lung adenocarcinoma group was significantly different from control group (P＜0.05), while there was no significant difference between the squamous cell carcinoma group and the control group (P＞0.05).There was no significantly statistical difference in the relative expression level of miR-375between lung squamous cell carcinoma group, lung adenocarcinoma group and the control group (P＞0.05).The AUC of serum miR-210of lung adenocarcinoma group was 0.737 5 (95％CI:0.498 3-0.976 7, P=0.091 4) with a medium diagnostic value.Conclusion MiR-210is highly expressed in the serum of patients with lung adenocarcinoma, suggesting that miR-210may be a novel tumor marker for the diagnosis of lung adenocarcinoma.The value of miR-375in the diagnosis of lung cancer still needs to be further explored.